This is further emphasised by the suggestion of a hitherto unreported link between overexpression of an NF-κB subunit and NF-κB activation, and should lead to increased efforts for the development and use of NF-κB inhibitory drugs to treat pancreatic cancer. The gene discussed is NFKB1; the disease is familial pancreatic carcinoma.